StefanKlausBartaMDMD, MS, MRCP(UK)

PubMed

• Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
  Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R Chong, Eugenio Fardella, Elise A Chong, Giulia Gabrielli, Sunita D Nasta, Daniel J Landsburg, Jord...> ;Journal of Hematology & Oncology. 2024 Apr 22
• Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T.
  Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T...> ;Blood Advances. 2024 Mar 26
• Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-...
  Brian Estrella, Mark M Francescone, Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Ahmed Sawas, Jennifer K Lue, Barbara Pro, Jennifer E Amengual> ;Leukemia & Lymphoma. 2024 Mar 22
• Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy.
  Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Pamela Blair Allen, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Br...> ;Blood Advances. 2024 Mar 18
• Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
  Elise A Chong, Emeline R Chong, Dylan Therwhangher, Sunita D Nasta, Daniel J Landsburg, Stefan K Barta, Jakub Svoboda, James N Gerson, Guido Ghilardi, Luca Paruzzo, Jo...> ;Transplantation and Cellular Therapy. 2024 Mar 16
• Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
  Elise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, Joseph Fabrizio, Aditi Gupta, Jakub Svoboda, Stefan K Barta, Kristy M Walsh, Ellen B Napier, Rachel K Lundber...> ;The Journal of Infectious Diseases. 2024 Mar 4
• 1 citations
  Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
  Sarah Aminov, Orsi Giricz, David T Melnekoff, R Alejandro Sica, Veronika Polishchuk, Cristian Papazoglu, Bonnie Yates, Hao-Wei Wang, Srabani Sahu, Yanhua Wang, Shanish...> ;The Journal of Clinical Investigation. 2024 Feb 20
• 1 citations
  Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
  Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E., Shestov, A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S., Porazzi, P., Landsburg, D., Gerson, J., Carter, J., Bart...> ;Blood Advances. 2024 Feb 13
• 5 citations
  T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
  Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette, Gabriel C Caponetti, Luca Paruzzo, Jaryse C Harris, Elise A Chong,...> ;Nature Medicine. 2024 Apr 1
• Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
  Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
• Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.
  Epperla, N., Narendranath Epperla, Qiuhong Zhao, Tamara Moyo, Marcus P Watkins, Montreh Tavakkoli, Celeste Bello, Pallawi Torka, Nishitha Reddy, Colin Thomas, Kaitlin ...> ;Blood Advances. 2024 Feb 13
• Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
  Stefan K Barta, Iyer, S., Johnston, P.> ;Blood Advances. 2024 Jan 23
• Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
  Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M Stephens, Catherine J Lee, Thomas Ollila, Geoffrey Shouse, Alexey V Danilov, Ke...> ;Journal of Hematology & Oncology. 2023 Nov 9
• Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
  Mathew G Angelos, Ruchi P Patel, Marco Ruella, Stefan K Barta> ;Transplantation and Cellular Therapy. 2024 Feb 1
• TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.
  Daniel J Landsburg, Jennifer Jd Morrissette, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Jakub Svoboda, Elise A Chong, Adam Bagg> ;Blood Advances. 2023 Dec 12
• 1 citations
  Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma ...
  Stefan K Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle Fanale, Kristina S Yu> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
• Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
  Kaitlin Annunzio, Natalie S Grover, Rina Li Welkie, Pallawi Torka, Marcus P Watkins, Andrea Anampa-Guzmán, Montreh Tavakkoli, Timothy S Oh, Heather Reves, Daniel Jones...> ;Blood Advances. 2023 Nov 28
• 3 citations
  2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
  Montreh Tavakkoli, Stefan K Barta> ;American Journal of Hematology. 2023 Nov 1
• Central Nervous System Relapse in T and NK cell Lymphomas.
  Eleanor P Taranto, Stefan K Barta, Rahul S Bhansali> ;Current Hematologic Malignancy Reports. 2023 Dec 1
• Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
  Jackson T Bowers, Jacob Anna, Steven M Bair, Kaitlin Annunzio, Narendranath Epperla, Jerrin Joy Pullukkara, Sameh Gaballa, Michael A Spinner, Shuning Li, Marcus R Mess...> ;Blood Advances. 2023 Nov 14
• 3 citations
  Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
  Narendranath Epperla, Qiuhong Zhao, Reem Karmali, Pallawi Torka, Lauren Shea, Timothy S Oh, Andrea Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Irl Brian Greenwell...> ;Blood Advances. 2023 Sep 12
• 2 citations
  SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas.
  Rahul S Bhansali, Stefan K Barta> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
• 1 citations
  Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or...
  Daniel J Landsburg, Sunita D Nasta, Jakub Svoboda, James N Gerson, Stephen J Schuster, Stefan K Barta, Elise A Chong, Heather Difilippo, Elizabeth Weber, Kathleen Cunn...> ;Transplantation and Cellular Therapy. 2023 Aug 1
• 6 citations
  Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
  Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S Oh, Heather Reaves, Montreh Tavakkoli,...> ;Journal of Hematology & Oncology. 2023 May 8
• Is it prime time for T-cell lymphoma?
  Stefan K Barta> ;Blood. 2023 May 4
• Join now to see all

Journal Articles

• Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib  
  Stefan Barta, MD, Clinical Pharmacokinetics
• Synergy of Sequential Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti- CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine M...  
  Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A, Leukemia & Lymphoma 2012 Oct; 53(10):1999-2003
• A phase I study of a combination of anti-CD19 and anti- CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.  
  Schindler J, Gajavelli S, Ravandi F, Shen YM, Parekh S, Braunschweig I, Barta S, Ghetie V, Vitetta E, Verma A, Br J Haematol 2011;154:471-6. PMID 21732928
• Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.  
  Barta SK, Yahalom J, Shia J, Hamlin PA, Clin Lymphoma Myeloma. 2006 Jul;7(1):77-82. PMID: 16879775
• Mood Changes following Acute Tryptophan Depletion in Healthy Adults.  
  Schmeck K, Sadigorsky S, Englert E, Demisch L, Dierks T, Barta S, Poustka F, Psychopathology 2002 July:35: 234-40. PMID: 12239440
• Survey of Patients? Views of Domiciliary Nebuliser Treatment for Chronic Lung Disease - a patients’ perspective on home nebulisers.  
  Barta S, Crawford A, Roberts M, Respiratory Medicine 2002 June:96:375-81. PMID: 12117035
• Intensity dependance of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects.  
  Dierks T, Barta S, Demisch L, Schmeck K, Englert E, Kewitz A, Maurer K, Poustka F, Psychopharmacology 1999 Sept:146:101-7. PMID: 10485971
• Join now to see all

Abstracts/Posters

• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 106
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ARL-IPI – A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab-Era.
  Barta SK, Xue X, Wang D, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Boue F, Wilson W, Wyen C, Dunleavy K, Sparano JA, ASH Annual Meeting, Atlanta
• A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors on Clinical Outcomes.
  Barta SK, Xue X, Wang D, Tamrari, R, Mounier N, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Weiss R, Galicier L, Boue F, Wilson W, Wyen C, Navarro JT, D..., ASH Annual Meeting 2012, Atlanta
• A Pooled Analysis of Treatment Factors Associated with Outcomes in 1144 Patients with HIV Associated Lymphoma.
  Barta SK, Xue X, Tamari R, Lee HY, Mounier N, Ribera JM, Spina R, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Sparano JA, ASCO Meeting Abstracts 2012;30:8005, American Society for Clinical Oncology (ASCO) Annual Meeting
• Synergy of Sequential and Concurrent Administration of a Deglycosylated Ricin A Chain- containing Combined Anti-CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabin...
  Barta SK, Zou Z, Schindler J, Bhagat T, Ghetie V, Vitetta SD, Verma A, American Society for Hematology (ASH) Annual Meeting December 2011, San Diego, CA
• Pooled Analysis of AIDS-Malignancy Consortium (AMC) Trials Evaluating Rituximab plus either CHOP or Infusional EPOCH Chemotherapy in HIV-Associated Non-Hodgkin’s Lymph...
  Barta SK, Lee JY, Sparano JA, Kaplan LD, Noy A, American Society for Hematology (ASH) Annual Meeting December 2010, Orlando, Fl
• Primary lung lymphomas: A clinicopathologic analysis of 61 cases, focusing on immunophenotype, cytogenetics and molecular genetics.
  Kotsali P, Barta SK, Teruya-Feldstein J, Hamlin PA, Fillipa DA, Meeting Abstract: 1140. Modern Pathology 2007 Mar:20: 249A-249A
• Do African Patients accept and adhere to HAART?
  Lomax N, Wheeler H, Barta SK, Leventis P, Chilton D, Adewakun A, Fakoya A, 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland
• Relationship between Intensity Dependence of Auditory Evoked Potentials and Impulsive and Aggressive Personality Traits.
  Barta S, Dierks T, Demisch L, Schmeck K, Englert E, Maurer K, Poustka F, Brain Topography 1997 Sept:10: 167-8
• Join now to see all

Lectures

• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinica... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic le... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all